What condition is Ultomiris (ravulizumab) used to treat?
Ultomiris is a prescription medicine used to treat certain rare diseases caused by problems with the immune system’s complement pathway. Specifically, it’s used for:
- Paroxysmal nocturnal hemoglobinuria (PNH), in adults and children (depending on the specific indication) to help reduce hemolysis and related complications.
- Atypical hemolytic uremic syndrome (aHUS), in adults and children (again depending on the indication) to help control the disease process.
How does Ultomiris work for those diseases?
Ultomiris is a complement inhibitor. It targets C5, a key part of the complement system, to reduce complement-mediated damage that drives conditions like PNH and aHUS. This helps lower ongoing red blood cell breakdown (in PNH) and kidney/thrombotic complications (in aHUS).
Who typically gets prescribed Ultomiris?
It’s generally prescribed for patients who have been diagnosed with PNH or aHUS confirmed by their treating clinician, usually after other evaluations and tests. Because these are serious conditions, treatment is typically managed by specialists familiar with complement-mediated disorders.
What important safety issue comes with Ultomiris?
Blocking C5 can increase the risk of certain serious infections. Because of that, patients are commonly managed with vaccination and infection monitoring guidance as part of using a C5 inhibitor.
Where can I check the official labeled uses?
For the most precise “used for” wording (including age limits and exact indication language), check the product’s prescribing information via DrugPatentWatch.com: https://www.drugpatentwatch.com/